君聖泰醫藥-B(02511.HK)與中國醫學科學院醫藥生物技術研究所開展科研課題合作，探索創新藥代謝與腎臟獲益潛力
格隆匯8月12日丨君聖泰醫藥-B(02511.HK)公吿，集團的全資附屬公司深圳君聖泰生物技術有限公司與中國醫學科學院醫藥生物技術研究所("藥生所")共同開展課題合作，評估集團核心產品HTD1801對糖尿病伴慢性腎病(CKDwithT2DM)的治療潛力。該項目已於近日在中國醫學科學院完成課題批准。基於本項目，雙方將圍繞糖尿病及伴慢性腎病適應症共同開展創新藥物的機制和臨牀研究，致力於探索具備綜合干預價值的創新治療方案。
本次合作聚焦糖腎代謝相關疾病的開發，依託藥生所在藥物研發和醫學的資源優勢，結合集團在代謝性疾病領域的核心競爭力和產品開發經驗，旨在加快創新治療方案在臨牀階段的推進，提升產品應用價值。根據合作協議，雙方圍繞異喹啉類新藥共同開展藥效與機制研究，並推進臨牀評估，以拓展其在糖尿病相關腎病領域的臨牀應用。此次合作將加快本集團核心項目的臨牀進展，拓展研發佈局，進一步豐富產品管線，為公司在代謝疾病治療領域的持續創新與長期發展提供有力支撐。
HTD1801是君聖泰醫藥核心產品，也是本次合作開發主要產品。它是一種靶向腸－肝系統的口服抗炎及代謝調節劑，具有全球首創的激活AMPK並抑制NLRP3炎症小體的獨特雙機制。全球開展的十餘項臨牀試驗顯示，HTD1801可同步改善血糖、血脂、腎功能、體重、肝功能、心血管、炎症等指標，展現出對2型糖尿病、慢性腎病、肥胖、血脂異常、脂肪肝等多個適應症的共病治療潛力。
中國醫學科學院成立於1956年，是我國最高醫學研究機構和領銜醫學教育機構。以引領我國醫學科技與教育發展和維護人民健康為己任，醫療領銜行業，為我國現代科學醫學體系的建立和發展做出了重要貢獻。
醫藥生物技術研究所(藥生所)是中國醫學科學院的直屬研究所，其重點領域是微生物藥物、抗感染藥物、與生物技術藥物研究，在國內一直保持相關學科和領域的研究優勢。藥生所具備綜合的新藥研究體系，在抗感染、抗代謝綜合徵、及抗癌等領域的新藥研發方面均取得重要進展，已成為不可替代的國家戰略科技力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
